Sichuan Hebang Biotechnology Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Sichuan Hebang Biotechnology.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
Chemicals winstgroei | 38.3% |
Inkomstengroei | n/a |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | None |
Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled
Sep 25Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story
Aug 16Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing
Jun 04Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)
May 13Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?
Mar 07Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock
Apr 21In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Sichuan Hebang Biotechnology onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
9/30/2024 | 9,203 | 486 | -933 | -205 | N/A |
6/30/2024 | 9,582 | 859 | -1,159 | -362 | N/A |
3/31/2024 | 8,429 | 916 | -1,572 | -700 | N/A |
12/31/2023 | 8,824 | 1,283 | -748 | 80 | N/A |
9/30/2023 | 8,980 | 1,398 | 272 | 886 | N/A |
6/30/2023 | 9,651 | 1,789 | 575 | 1,246 | N/A |
3/31/2023 | 12,347 | 3,161 | 1,541 | 2,383 | N/A |
12/31/2022 | 13,039 | 3,807 | 1,708 | 2,644 | N/A |
9/30/2022 | 13,353 | 4,438 | 773 | 2,970 | N/A |
6/30/2022 | 13,517 | 4,741 | 1,682 | 3,670 | N/A |
3/31/2022 | 11,409 | 3,815 | 1,535 | 3,537 | N/A |
12/31/2021 | 9,987 | 3,018 | 1,462 | 3,271 | N/A |
9/30/2021 | 8,494 | 2,248 | 1,975 | 2,627 | N/A |
6/30/2021 | 6,768 | 908 | 1,276 | 1,829 | N/A |
3/31/2021 | 5,902 | 319 | 685 | 843 | N/A |
12/31/2020 | 5,261 | 41 | 172 | 369 | N/A |
9/30/2020 | 5,115 | -147 | -307 | 79 | N/A |
6/30/2020 | 5,351 | 264 | -572 | 13 | N/A |
3/31/2020 | 5,565 | 372 | -668 | 11 | N/A |
12/31/2019 | 5,969 | 517 | -500 | 163 | N/A |
9/30/2019 | 6,200 | 380 | -243 | 378 | N/A |
6/30/2019 | 6,154 | 387 | 40 | 488 | N/A |
3/31/2019 | 6,285 | 426 | 537 | 954 | N/A |
12/31/2018 | 6,009 | 363 | 581 | 944 | N/A |
9/30/2018 | 5,990 | 622 | 574 | 967 | N/A |
6/30/2018 | 5,625 | 535 | N/A | 1,005 | N/A |
3/31/2018 | 4,961 | 395 | N/A | 378 | N/A |
12/31/2017 | 4,738 | 518 | N/A | 177 | N/A |
9/30/2017 | 4,400 | 477 | N/A | 189 | N/A |
6/30/2017 | 4,041 | 451 | N/A | 247 | N/A |
3/31/2017 | 3,722 | 436 | N/A | 270 | N/A |
12/31/2016 | 3,463 | 318 | N/A | 575 | N/A |
9/30/2016 | 3,206 | 260 | N/A | 558 | N/A |
6/30/2016 | 2,954 | 226 | N/A | 248 | N/A |
3/31/2016 | 3,043 | 255 | N/A | 548 | N/A |
12/31/2015 | 2,863 | 240 | N/A | 449 | N/A |
9/30/2015 | 2,757 | 144 | N/A | 173 | N/A |
6/30/2015 | 2,628 | 135 | N/A | 325 | N/A |
3/31/2015 | 2,282 | 679 | N/A | -9 | N/A |
12/31/2014 | 2,186 | 672 | N/A | 205 | N/A |
9/30/2014 | 1,979 | 715 | N/A | -20 | N/A |
6/30/2014 | 1,871 | 696 | N/A | -172 | N/A |
3/31/2014 | 1,660 | 54 | N/A | -121 | N/A |
12/31/2013 | 1,603 | 64 | N/A | -407 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if 603077's forecast earnings growth is above the savings rate (2.9%).
Winst versus markt: Insufficient data to determine if 603077's earnings are forecast to grow faster than the CN market
Hoge groeiwinsten: Insufficient data to determine if 603077's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if 603077's revenue is forecast to grow faster than the CN market.
Hoge groei-inkomsten: Insufficient data to determine if 603077's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 603077's Return on Equity is forecast to be high in 3 years time